World Lung Cancer Congress 2020: Keytruda combined chemotherapy doubles the survival of advanced NSCLC

Both globally and in China, lung cancer is the most common malignant tumor, and is the leading cause of cancer death, of which non-small cell lung cancer (NSCLC) accounts for about 80% to 85% of the total number of lung cancer.
latest statistics from the National Cancer Center, about 787,000 new lung cancer patients died of lung cancer in China in 2015.
according to the Code of Diagnosis and Treatment of Primary Lung Cancer (2018 Edition), the five-year survival rate of late-stage patients in NSCLC patients in China is only about 5%, and the treatment status quo needs to be improved urgently.
At last year's North American Lung Cancer Conference, data on the long-term survival of the first-line treatment of advanced NSCLC in pembrolizumab (Keytruda, or K-drug) was published: more than half of patients survived more than three years, significantly reducing the risk of death by 29% compared to chemotherapy.
results from the KEYNOTE-021G cohort study, published simultaneously in the journal Journal of Thoracic Oncology, a journal of the International Association for Lung Cancer Research (IASLC).
asCO, Mercadon released the final results of its key Phase III clinical trial KEYNOTE-189.
studies have shown that combined chemotherapy with the K drug continues to improve OS, PFS, ORR, and PFS2 in patients compared to placebo combination chemotherapy, while adverse reactions are easy to manage.
Recently, at the 2020 World Lung Cancer Congress (WCLC) held by the International Lung Cancer Research Association (IASLC), the KEYNOTE-189 trial published the latest four-year follow-up results: In first-line treatment, combined chemotherapy with the K drug doubles the survival of patients with advanced NSCLC and provides sustained survival benefits.
data also included 56 patients who completed all 35 cycles (2 years) of K-drug treatment and found that the total remission rate for such patients was 87.5 percent, of which 10.7 percent were fully remission and 76.8 percent were partially relieved.
, the combined treatment improved the overall remission rate and duration, regardless of PD-L1 expression level.
after a medium follow-up period of 46.3 months, the mid-OS in the combined treatment group was 22.0 months, the chemotherapy group was 10.6 months, and the combined treatment reduced the risk of death by 40 percent.
, the mean PFS in the combined treatment group and the chemotherapy group was 9.0 months and 4.9 months, respectively, and the risk of disease progressity or death in the combined treatment group was reduced by 50%.
3-year OS rate was 31.3% vs 17.4% for the combined treatment group and the individual chemotherapy group, and the estimated three-year PFS was 11.8% vs 1.3%.
, about 117 patients (57%) in the individual chemotherapy group received follow-up anti-PD-1 or anti-PD-L1 treatment, which also included people who used the K drug.
"Compared to placebo plus chemotherapy, combined chemotherapy with K continues to provide the benefits of OS and PFS," said Dr. Johanelle Gray, co-leader of the Chemical Biology and Molecular Medicine Program and head of the Department of Chest Oncology at Moffett Cancer Center, introducing the data.
patients who received 35 cycles of K-drugs maintained a long-lasting response to the drug, while safety was controlled.
" in addition, patients in each PD-L1 expression group could benefit from the K drug.
PD-L1 Tumor Ratio Score (TPS) ≥50% of patients, the mid-OS using K-drug combination therapy and chemotherapy alone was 27.7 months and 10.1 months (HR=0.71; 95% CI, 0.50-50-1.00);PD-L1 TPS between 1% and 49% of patients, the middle OS is 21.8 months and 12.1 months (HR s 0.66; 95% CI, 0.47-0.93).
PD-L1 TPS<1% group was corresponding to 17.2 months and 10.2 months (HR s 0.52; 95% CI, 0.37-0.72).
, current studies have shown that combination chemotherapy for the K drug may be licensed as the standard treatment for newly diagnosed metastasis non-squamous non-small cell lung cancer patients.
: Pembrolizumab Combo Continues to Drive OS Benefit in Nonsqamous NSCLC Versus Processy Alone MedSci Original Source: MedSci Original Copyright Notice: All noted on this website "Source: The text, images and audio and video materials of Metz Medicine or Source: MedSci Originals are owned by Metz Medicine and may not be reproduced by any media, website or individual without authorization, and shall be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
reproduce content at the same time does not represent the position of this site.
leave a message here